Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for Hiv/Aids Drugs
33 Pages Posted: 19 Feb 2006 Last revised: 10 Apr 2022
Date Written: December 2005
Abstract
The social value of an innovation is comprised of the value to consumers and the value to innovators. We estimate that for the HIV/AIDS therapies that entered the market from the late 1980's onwards, innovators appropriated only 5% of the social surplus arising from these new technologies. Despite the high annual costs of these drugs to patients, the low share of social surplus going to innovators raises concerns about advocating cost-effectiveness criteria that would further reduce this share, and hence further reduce incentives for innovation.
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
Accounting for Future Costs in Medical Cost-Effectiveness Analysis
-
Schumpeterian Profits in the American Economy: Theory and Measurement
-
Schumpeterian Profits in the American Economy: Theory and Measurement
-
Estimating the Impact of Medical Innovation: A Case Study of HIV Antiretroviral Treatments
By Mark Duggan and William N. Evans
-
Insurance and Incentives for Medical Innovation
By Alan M. Garber, Charles I. Jones, ...
-
Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets
-
Advances in Cost-Effectiveness Analysis of Health Interventions
-
The Welfare Effects of Public Drug Insurance
By Darius N. Lakdawalla and Neeraj Sood
-
Surplus Appropriation from R&D and Health Care Technology Assessment Procedures
By Tomas Philipson and Anupam B. Jena